[Local express auto-cytokine therapy (a complex of cytokines) in the treatment of viral and nonviral eye lesions].
The method of local express-autocytocinetherapy (LEACCT) consists in using an experimentally tested autologous complex of cytokines (alpha- beta- gamma-interferons, interleukins 2.8, tumor necrosis factor gamma etc.), which is produced by joining the autoblood of patients with immune-modulator poludan (complex poly A:poly U). The external LEACCT and the intrachamber LEACCT are distinguished. The former presupposes the administration (subconjunctivally and in installations) of the autoblood-poludan mixture. This method is used in herpes- and adenovirus keratoconjunctivitis, slow re-epithelization after laser keratectomy and in eye burns (178 patients). The latter comprises, apart from the external LEACCT procedures, a 1-4-time introduction of the mentioned mixture into patient's anterior chamber. It was used in endothelial herpetic keratoiridocyclitis, initial bullous keratopathy, severe keratoconus and in injuries of the anterior lens capsule (117 patients). The clinical-study results (main group--295 patients) show that the designed method based on poludan has pronounced anti-inflammatory and regenerative effects in different viral and virus-free lesions of the eye tissues; it is simple and can be applied in clinical settings. An increased visual acuity ranging from 0.05 to 1.0 was registered in 85% of cases. The action of the complex of cytokines is as close as possible to the physiological mechanism, which provides for avoiding the side-effects and for applying the treatment scheme in situations when the administration of other drugs is limited or their efficiency is not sufficient.
Kasparov
A A
AA
Kasparova
Evg A
EA
Pavliuk
A S
AS
D000257:Adenoviridae Infections / Q000188:drug therapy; D003236:Conjunctivitis, Viral / Q000188:drug therapy; D016207:Cytokines / Q000008:administration & dosage / Q000627:therapeutic use*; D005126:Eye Burns / Q000188:drug therapy; D005128:Eye Diseases / Q000188:drug therapy*; D015817:Eye Infections / Q000188:drug therapy; D005131:Eye Injuries / Q000188:drug therapy; D006801:Humans; D007369:Interferon Inducers / Q000008:administration & dosage / Q000627:therapeutic use*; D016849:Keratitis, Herpetic / Q000188:drug therapy; D007637:Keratoconjunctivitis / Q000188:drug therapy; D007640:Keratoconus / Q000188:drug therapy; D011131:Polyribonucleotides / Q000008:administration & dosage / Q000627:therapeutic use*; D014792:Visual Acuity
D016207:Cytokines; D007369:Interferon Inducers; D011131:Polyribonucleotides; C044366:poludan